Collabrx Inc (CLRX) 0.48 $CLRX
CollabRx Announces Adrienne Craig-Kennard as Vice President of Global Business Development and Strategic Alliances
GlobeNewswire - Tue Jan 19, 6:00AM CST
CollabRx, Inc., a leading clinical decision support company and wholly owned subsidiary of Rennova Health, Inc. (NASDAQ:RNVA) today announced Adrienne Craig-Kennard will serve as Vice President of Global Business Development and Strategic Alliances.
RNVA: 0.26 (unch), CLRX: 0.48 (+0.05)
CollabRx Chief Medical Officer to Moderate Panel at Personalized Medicine World Conference (PMWC) 2016
GlobeNewswire - Thu Dec 10, 6:00AM CST
CollabRx, Inc. a leading clinical decision support company and wholly owned subsidiary of Rennova Health, Inc. (NASDAQ:RNVA) today announced that its Chief Medical Officer, George Lundberg, MD, will chair this year's Personalized Medicine World Conference, Silicon Valley session titled, "The Role of Practicing Pathologists in Personalized Medicine."
RNVA: 0.26 (unch), CLRX: 0.48 (+0.05)
CollabRx Stockholders Approve Merger With Medytox Solutions
GlobeNewswire - Fri Oct 30, 4:58PM CDT
CollabRx, Inc. ("CollabRx"
(NASDAQ:CLRX) announced today it held its Special Meeting of Stockholders to approve the following proposals: (1) the issuance of shares of CollabRx common stock and other securities exercisable or convertible for shares of CollabRx common stock in connection with the proposed merger with Medytox Solutions, Inc. ("Medytox"; (2) an amendment to the CollabRx Certificate of Incorporation, as amended, to effect a reverse split of CollabRx's common stock at a specific ratio from 1-for-2.5 to 1-for-10, to be effected immediately prior to the effective time of the merger; (3) an amendment to CollabRx's Certificate of Incorporation to increase the number of authorized shares of CollabRx common stock from 50,000,000 to 150,000,000 shares, effective as of the effective time of the merger; (4) an amendment to the CollabRx 2007 Incentive Award Plan to increase the number of shares authorized to be issued under the plan and to increase the maximum number of shares any one individual may receive in any calendar year, effective as of the effective time of the merger; (5) to vote upon in an advisory (non-binding) basis the "golden parachute" compensation that may become payable to CollabRx's named executive officers in connection with the Merger Agreement as required by Item 402(t) of Regulation S-K and Section 14A(b) of the Securities Exchange Act of 1934, as amended; and (6) the adjournment of the special meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies in favor of the foregoing proposals.
CLRX: 0.48 (+0.05)
Medytox Solutions, Inc. Stockholders Approve Merger With CollabRx, Inc.
Marketwired - Wed Oct 28, 4:38PM CDT
Medytox Solutions, Inc. (OTCQB: MMMS) ("Medytox" announced today it held its Special Meeting of Stockholders to approve the following proposals: (i) to approve and adopt the Agreement and Plan of Merger, dated as of April 15, 2015, by and among CollabRx, Inc., CollabRx Merger Sub, Inc., a direct wholly owned subsidiary of CollabRx formed for the purpose of the merger, and Medytox (the "Merger Agreement", pursuant to which Medytox will become a wholly owned subsidiary of CollabRx (the "Merger", and the transactions contemplated by such agreement (the "Merger Proposal" and (ii) to approve any motion to adjourn the Special Meeting, or any adjournment thereof, to another time or place if necessary or appropriate to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve and adopt the Merger Agreement and the transactions contemplated thereby (the "Adjournment Proposal".
CLRX: 0.48 (+0.05)
CollabRx Adjourns Stockholder Special Meeting to October 30, 2015
GlobeNewswire - Wed Oct 28, 4:06PM CDT
CollabRx, Inc. ("CollabRx" (NASDAQ:CLRX) announced today that the special meeting of its stockholders scheduled for Wednesday, October 28, 2015 to consider and act on several proposals recommended by CollabRx's board and management regarding its proposed merger with Medytox Solutions, Inc. ("Medytox" (OTCQB:MMMS) has been adjourned to Friday, October 30, 2015 at 10:30 am Pacific Time, and will take place at CollabRx's offices located at 44 Montgomery Street, Suite 800, San Francisco, CA 94104-4811.
CLRX: 0.48 (+0.05)
CollabRx Stockholder Special Meeting to be Held October 28, 2015
GlobeNewswire - Thu Oct 22, 6:09AM CDT
As previously announced, CollabRx, Inc. ("CollabRx" (NASDAQ:CLRX) will hold a special meeting of its stockholders on Wednesday, October 28, 2015, to consider and act on several proposals recommended by CollabRx's board and management regarding its proposed merger with Medytox Solutions, Inc. ("Medytox" (OTCQB:MMMS).
CLRX: 0.48 (+0.05)
CollabRx Announces Special Meeting of Its Stockholders to Be Held October 28, 2015
GlobeNewswire - Thu Sep 24, 5:00PM CDT
CollabRx, Inc. ("CollabRx" (NASDAQ:CLRX) today announced that the registration statement on Form S-4 and the definitive joint proxy statement/prospectus contained therein, regarding CollabRx's proposed merger with Medytox Solutions, Inc. ("Medytox" (OTCQB:MMMS), has been declared effective by the Securities and Exchange Commission (the "SEC".
CLRX: 0.48 (+0.05)
Omnicell Q2 Earnings Miss, Revenues Up Y/Y; View Retained - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 03, 11:50AM CDT
Omnicells's (OMCL) Revenues increased 7.4% year over year to $112.8 million in the quarter, but missed the Zacks Consensus Estimate of $121 million.
CLRX: 0.48 (+0.05), MDRX: 12.91 (unch), MRGE: 7.12 (-0.01), OMCL: 38.30 (+0.72)
Allscripts Healthcare (MDRX) Jumps: Stock Rises 9.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 20, 8:39AM CDT
Allscripts Healthcare Solutions, Inc. (MDRX) was a big mover last session, as the company saw its shares rise more than 9% on the day.
CLRX: 0.48 (+0.05), MDRX: 12.91 (unch)
Cerner's Millennium EHR Deal with AUVA Boosts Austria Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 16, 11:00AM CDT
Cerner Corp's (CERN) Millennium electronic health record (EHR) was recently selected by Vienna, Austria-based AUVA.
CLRX: 0.48 (+0.05), QCOM: 63.47 (+0.40), CERN: 65.01 (+0.47), ATHN: 123.13 (+0.70)
CollabRx Announces Receipt of NASDAQ Notice of Noncompliance for Bid Price
GlobeNewswire - Fri Jun 05, 6:00AM CDT
CollabRx, Inc. (Nasdaq:CLRX) (herein "CLRX" or "the Company", announced today that it received a letter from The NASDAQ Stock Market LLC ("Nasdaq" stating that the bid price of the Company's common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued listing under Listing Rule 5550(a)(2).
CLRX: 0.48 (+0.05)
CollabRx Receives Notice From Nasdaq on Change of Control
GlobeNewswire - Wed Apr 29, 6:01AM CDT
CollabRx, Inc. (Nasdaq:CLRX) ("CollabRx" or "the Company", today announced that it had received notice from The NASDAQ Stock Market LLC ("Nasdaq" that the Company's proposed transaction with Medytox Solutions, Inc. (OTCQB:MMMS) ("Medytox" when completed would constitute a business combination that results in a "change of control" as that term is defined in Nasdaq Listing Rule 5110(a). Accordingly, the post-transaction entity would be required to successfully complete the Nasdaq listing application process and satisfy all criteria for initial listing on Nasdaq.
CLRX: 0.48 (+0.05)
CollabRx and Medytox Solutions Sign Definitive Merger Agreement
GlobeNewswire - Thu Apr 16, 6:00AM CDT
CollabRx, Inc. (Nasdaq:CLRX) ("CollabRx" and Medytox Solutions, Inc. (OTCQB: MMMS) ("Medytox" today announced that they have entered into a definitive merger agreement. Closing of the merger is subject to, among other things, gaining stockholder approvals from both companies, receipt of regulatory approvals and other customary closing conditions.
CLRX: 0.48 (+0.05)
Medytox Solutions Signs Definitive Merger Agreement With CollabRx
GlobeNewswire - Thu Apr 16, 6:00AM CDT
Medytox Solutions, Inc. (OTCQB:MMMS) ("Medytox" and CollabRx, Inc. (Nasdaq:CLRX) ("CollabRx" today announced that they have entered into a definitive merger agreement. Closing of the merger is subject to, among other things, gaining stockholder approvals from both companies, receipt of regulatory approvals and other customary closing conditions.
CLRX: 0.48 (+0.05)
CollabRx Announces Adrienne Craig-Kennard as Vice President of Global Business Development and Strategic Alliances
GlobeNewswire - Tue Jan 19, 6:00AM CST
CollabRx, Inc., a leading clinical decision support company and wholly owned subsidiary of Rennova Health, Inc. (NASDAQ:RNVA) today announced Adrienne Craig-Kennard will serve as Vice President of Global Business Development and Strategic Alliances.
RNVA: 0.26 (unch), CLRX: 0.48 (+0.05)
CollabRx Chief Medical Officer to Moderate Panel at Personalized Medicine World Conference (PMWC) 2016
GlobeNewswire - Thu Dec 10, 6:00AM CST
CollabRx, Inc. a leading clinical decision support company and wholly owned subsidiary of Rennova Health, Inc. (NASDAQ:RNVA) today announced that its Chief Medical Officer, George Lundberg, MD, will chair this year's Personalized Medicine World Conference, Silicon Valley session titled, "The Role of Practicing Pathologists in Personalized Medicine."
RNVA: 0.26 (unch), CLRX: 0.48 (+0.05)
CollabRx Stockholders Approve Merger With Medytox Solutions
GlobeNewswire - Fri Oct 30, 4:58PM CDT
CollabRx, Inc. ("CollabRx"
(NASDAQ:CLRX) announced today it held its Special Meeting of Stockholders to approve the following proposals: (1) the issuance of shares of CollabRx common stock and other securities exercisable or convertible for shares of CollabRx common stock in connection with the proposed merger with Medytox Solutions, Inc. ("Medytox"; (2) an amendment to the CollabRx Certificate of Incorporation, as amended, to effect a reverse split of CollabRx's common stock at a specific ratio from 1-for-2.5 to 1-for-10, to be effected immediately prior to the effective time of the merger; (3) an amendment to CollabRx's Certificate of Incorporation to increase the number of authorized shares of CollabRx common stock from 50,000,000 to 150,000,000 shares, effective as of the effective time of the merger; (4) an amendment to the CollabRx 2007 Incentive Award Plan to increase the number of shares authorized to be issued under the plan and to increase the maximum number of shares any one individual may receive in any calendar year, effective as of the effective time of the merger; (5) to vote upon in an advisory (non-binding) basis the "golden parachute" compensation that may become payable to CollabRx's named executive officers in connection with the Merger Agreement as required by Item 402(t) of Regulation S-K and Section 14A(b) of the Securities Exchange Act of 1934, as amended; and (6) the adjournment of the special meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies in favor of the foregoing proposals. CLRX: 0.48 (+0.05)
Medytox Solutions, Inc. Stockholders Approve Merger With CollabRx, Inc.
Marketwired - Wed Oct 28, 4:38PM CDT
Medytox Solutions, Inc. (OTCQB: MMMS) ("Medytox"
announced today it held its Special Meeting of Stockholders to approve the following proposals: (i) to approve and adopt the Agreement and Plan of Merger, dated as of April 15, 2015, by and among CollabRx, Inc., CollabRx Merger Sub, Inc., a direct wholly owned subsidiary of CollabRx formed for the purpose of the merger, and Medytox (the "Merger Agreement", pursuant to which Medytox will become a wholly owned subsidiary of CollabRx (the "Merger", and the transactions contemplated by such agreement (the "Merger Proposal" and (ii) to approve any motion to adjourn the Special Meeting, or any adjournment thereof, to another time or place if necessary or appropriate to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve and adopt the Merger Agreement and the transactions contemplated thereby (the "Adjournment Proposal". CLRX: 0.48 (+0.05)
CollabRx Adjourns Stockholder Special Meeting to October 30, 2015
GlobeNewswire - Wed Oct 28, 4:06PM CDT
CollabRx, Inc. ("CollabRx"
(NASDAQ:CLRX) announced today that the special meeting of its stockholders scheduled for Wednesday, October 28, 2015 to consider and act on several proposals recommended by CollabRx's board and management regarding its proposed merger with Medytox Solutions, Inc. ("Medytox" (OTCQB:MMMS) has been adjourned to Friday, October 30, 2015 at 10:30 am Pacific Time, and will take place at CollabRx's offices located at 44 Montgomery Street, Suite 800, San Francisco, CA 94104-4811. CLRX: 0.48 (+0.05)
CollabRx Stockholder Special Meeting to be Held October 28, 2015
GlobeNewswire - Thu Oct 22, 6:09AM CDT
As previously announced, CollabRx, Inc. ("CollabRx"
(NASDAQ:CLRX) will hold a special meeting of its stockholders on Wednesday, October 28, 2015, to consider and act on several proposals recommended by CollabRx's board and management regarding its proposed merger with Medytox Solutions, Inc. ("Medytox" (OTCQB:MMMS). CLRX: 0.48 (+0.05)
CollabRx Announces Special Meeting of Its Stockholders to Be Held October 28, 2015
GlobeNewswire - Thu Sep 24, 5:00PM CDT
CollabRx, Inc. ("CollabRx"
(NASDAQ:CLRX) today announced that the registration statement on Form S-4 and the definitive joint proxy statement/prospectus contained therein, regarding CollabRx's proposed merger with Medytox Solutions, Inc. ("Medytox" (OTCQB:MMMS), has been declared effective by the Securities and Exchange Commission (the "SEC". CLRX: 0.48 (+0.05)
Omnicell Q2 Earnings Miss, Revenues Up Y/Y; View Retained - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 03, 11:50AM CDT
Omnicells's (OMCL) Revenues increased 7.4% year over year to $112.8 million in the quarter, but missed the Zacks Consensus Estimate of $121 million.
CLRX: 0.48 (+0.05), MDRX: 12.91 (unch), MRGE: 7.12 (-0.01), OMCL: 38.30 (+0.72)
Allscripts Healthcare (MDRX) Jumps: Stock Rises 9.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 20, 8:39AM CDT
Allscripts Healthcare Solutions, Inc. (MDRX) was a big mover last session, as the company saw its shares rise more than 9% on the day.
CLRX: 0.48 (+0.05), MDRX: 12.91 (unch)
Cerner's Millennium EHR Deal with AUVA Boosts Austria Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 16, 11:00AM CDT
Cerner Corp's (CERN) Millennium electronic health record (EHR) was recently selected by Vienna, Austria-based AUVA.
CLRX: 0.48 (+0.05), QCOM: 63.47 (+0.40), CERN: 65.01 (+0.47), ATHN: 123.13 (+0.70)
CollabRx Announces Receipt of NASDAQ Notice of Noncompliance for Bid Price
GlobeNewswire - Fri Jun 05, 6:00AM CDT
CollabRx, Inc. (Nasdaq:CLRX) (herein "CLRX" or "the Company"
, announced today that it received a letter from The NASDAQ Stock Market LLC ("Nasdaq" stating that the bid price of the Company's common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued listing under Listing Rule 5550(a)(2). CLRX: 0.48 (+0.05)
CollabRx Receives Notice From Nasdaq on Change of Control
GlobeNewswire - Wed Apr 29, 6:01AM CDT
CollabRx, Inc. (Nasdaq:CLRX) ("CollabRx" or "the Company"
, today announced that it had received notice from The NASDAQ Stock Market LLC ("Nasdaq" that the Company's proposed transaction with Medytox Solutions, Inc. (OTCQB:MMMS) ("Medytox" when completed would constitute a business combination that results in a "change of control" as that term is defined in Nasdaq Listing Rule 5110(a). Accordingly, the post-transaction entity would be required to successfully complete the Nasdaq listing application process and satisfy all criteria for initial listing on Nasdaq. CLRX: 0.48 (+0.05)
CollabRx and Medytox Solutions Sign Definitive Merger Agreement
GlobeNewswire - Thu Apr 16, 6:00AM CDT
CollabRx, Inc. (Nasdaq:CLRX) ("CollabRx"
and Medytox Solutions, Inc. (OTCQB: MMMS) ("Medytox" today announced that they have entered into a definitive merger agreement. Closing of the merger is subject to, among other things, gaining stockholder approvals from both companies, receipt of regulatory approvals and other customary closing conditions. CLRX: 0.48 (+0.05)
Medytox Solutions Signs Definitive Merger Agreement With CollabRx
GlobeNewswire - Thu Apr 16, 6:00AM CDT
Medytox Solutions, Inc. (OTCQB:MMMS) ("Medytox"
and CollabRx, Inc. (Nasdaq:CLRX) ("CollabRx" today announced that they have entered into a definitive merger agreement. Closing of the merger is subject to, among other things, gaining stockholder approvals from both companies, receipt of regulatory approvals and other customary closing conditions. CLRX: 0.48 (+0.05)
